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Despite advances in the field of male reproductive health, idiopathic male infertility, in which a man has altered semen 
characteristics without an identifiable cause and there is no female factor infertility, remains a challenging condition to diag-
nose and manage. Increasing evidence suggests that oxidative stress (OS) plays an independent role in the etiology of male 
infertility, with 30% to 80% of infertile men having elevated seminal reactive oxygen species levels. OS can negatively affect 
fertility via a number of pathways, including interference with capacitation and possible damage to sperm membrane and 
DNA, which may impair the sperm’s potential to fertilize an egg and develop into a healthy embryo. Adequate evaluation of 
male reproductive potential should therefore include an assessment of sperm OS. We propose the term Male Oxidative Stress 
Infertility, or MOSI, as a novel descriptor for infertile men with abnormal semen characteristics and OS, including many 
patients who were previously classified as having idiopathic male infertility. Oxidation-reduction potential (ORP) can be a 
useful clinical biomarker for the classification of MOSI, as it takes into account the levels of both oxidants and reductants 
(antioxidants). Current treatment protocols for OS, including the use of antioxidants, are not evidence-based and have the 
potential for complications and increased healthcare-related expenditures. Utilizing an easy, reproducible, and cost-effective 
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INTRODUCTION
Natural conception is a complex process that is 
achieved in only 76% to 85% of  couples within 12 
months of regular unprotected intercourse [1-5]. The In-
ternational Committee for Monitoring Assisted Repro-
ductive Technologies (ICMART) defines infertility as 
the inability to conceive after 1 year of regular, unpro-
tected intercourse [6,7]. The World Health Organization 
estimates that nearly 190 million people struggle with 
infertility worldwide and the number of couples seek-
ing medical assistance is steadily rising [8,9]. Among 
couples unable to conceive, infertility is partially or 
wholly attributable to a male factor in approximately 
50% of cases (Fig. 1) [10-12]. A variety of conditions can 
affect male reproductive potential to different extent 
and they often coexist (Fig. 2) [13-19]. Paradoxically, 
on routine assessment, the precise etiology of male 
factor infertility remains undefined in 30% to 50% of 
patients, who are subsequently classified as having 
test to measure ORP may provide a more targeted, reliable approach for administering antioxidant therapy while minimizing 
the risk of antioxidant overdose. With the increasing awareness and understanding of MOSI as a distinct male infertility diag-
nosis, future research endeavors can facilitate the development of evidence-based treatments that target its underlying cause.
Keywords: Infertility, male; MOSI; Oxidation reduction potential; Oxidative stress; Semen
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which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fig. 1. World map containing percentag-
es of infertility cases per region that are 
due to male factor involvement among 
regions studied. Asia includes all of Rus-
sia. Data from Agarwal et al (Reprod Biol 
Endocrinol 2015;13:37) [10].
Fig. 2. Conditions affecting male reproductive potential. 
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idiopathic male infertility [20-22]. Unlike unexplained 
male infertility with its normal semen parameters, id-
iopathic male infertility is diagnosed in the presence of 
altered semen characteristics without an identifiable 
cause and the absence of female factor infertility [23].
THE CONCEPT OF MALE OXIDATIVE 
STRESS INFERTILITY (MOSI)
There is overwhelming evidence that oxidative stress 
(OS) plays a significant role in the etiology of male in-
fertility [24-30]. Seminal reactive oxygen species (ROS) 
are produced mainly by leukocytes or abnormal and 
immature spermatozoa, and are a natural byproduct 
of oxidative metabolic pathways as well as cytosolic 
and plasma membrane oxidases [31-34]. ROS are also a 
natural byproduct of adenosine triphosphate produc-
tion within sperm cell mitochondria [35]. Small quan-
tities of ROS are required to ensure normal cellular 
physiological functions, including spermatogenesis and 
various sperm functions preceding fertilization, such 
as capacitation and acrosome reaction [32,36-38]. When 
ROS levels increase to a pathological level, the body 
uses dietary and endogenously produced antioxidants 
to bring the system back to homeostasis [39]. An im-
balance between these two opposing forces, in which 
ROS outweigh antioxidants, can result in OS, which 
can negatively affect fertility via a number of path-
ways. OS interferes with capacitation and may cause 
sperm membrane and DNA damage, thereby affecting 
the sperm’s potential to fertilize an egg and generate 
a healthy embryo [32,40-45]. Also, OS can trigger for-
mation of genotoxic and mutagenic byproducts in the 
sperm that may increase the risk of disease in the off-
spring [46]. Depending on the assay methodology used, 
recent literature suggests that 30% to 80% of infertile 
men have elevated seminal ROS levels, a potentially 
treatable condition [28,30,44,47-56]. A similarly high 
incidence of OS was reported in a recent clinical trial, 
with 83.8% (124 of 148 cases) of idiopathic infertile men 
having positive seminal oxidation-reduction potential 
(ORP), a measure of ROS-antioxidant discrepancy [un-
published data]. 
Male reproductive potential cannot be adequately 
assessed if seminal OS is overlooked. However, there is 
currently no consensus concerning either the preferred 
method to measure OS in the clinical setting nor the 
diagnostic terminology to define this condition. There-
fore, we propose the term Male Oxidative Stress Infer-
tility, or MOSI, as a novel descriptor for infertile men 
with abnormal semen characteristics and OS, which in-
cludes many patients who were previously classified as 
having idiopathic male infertility (Appendix) [24,52,57-
59]. Based on several epidemiologic studies, OS may be 
present in about 56 million males complaining of infer-
tility, two-thirds of whom are considered to have MOSI 
(https://www.nichd.nih.gov/health/topics/menshealth/
conditioninfo/infertility) (Fig. 3) [30,60-63]. In men with 
normal semen characteristics who are part of couples 
experiencing unexplained infertility, the role of OS is 
not well defined. In our experience, 29.4% (10 of 34) of 
men in this group have leukocytospermia as opposed to 
50% 30% 20%
186 Million infertile couples
Rutstein and Shah
(World Health Organization, 2004) [9]
Male factor infertility (50%)
93 million
Agarwal et al
(Reprod Biol Endocrinol
2015;13:37) [10]
Jarow et al
(American Urological
Association, 2011) [63]
C
Cleveland
Clinic
2019
NIH
a
Oxidative stress: 80%
Ko et al
(Fertil Steril
2014;102:1518-2) [60]
Wagner et al
(Arab J Urol
2017;16:35-43) [30]
Oxidative stress:
30% 40%
18.6
Million
Agarwal et al
(World J Mens Health
2014;32:1-17) [62]
MOSI
Male oxidative
stress infertility
Known or unexplained
causes (50%) 46.5 million
Idiopathic (50%)
46.5 million
37.2
Million
Fig. 3. Worldwide incidence of MOSI in infertile men. aNational Institutes of Health (NIH) (https://www.nichd.nih.gov/health/topics/menshealth/
conditioninfo/infertility) [61], Agarwal et al (2014) [60], Jarow et al (2011) [63]. 
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12.2% (77 of 629) in the general population of men with 
infertility [unpublished data]. 
DIAGNOSIS OF MALE OXIDATIVE 
STRESS INFERTILITY (MOSI)
Conventional semen analysis was introduced about 
a century ago and remains the most widely used test 
for measuring sperm production and quality. In recent 
years, it has become clear that conventional semen 
analysis alone is not an adequate surrogate measure 
of male fecundity [64], as it is plagued with critical 
shortcomings such as poor reproducibility, subjectiv-
ity, and poor prediction of fertility [65-68]. Given the 
limited clinical utility of conventional semen analysis 
and the pathological consequences and ubiquity of OS 
among the subfertile male population, we propose the 
incorporation of ORP as a useful clinical biomarker 
for MOSI in men with abnormal semen analysis and 
male infertility [58,69-72]. ORP may be used to measure 
the levels of reductants (antioxidants) and oxidants in 
a variety of biological fluids [73] and could become an 
adjunct component of semen analysis due to its robust 
association with impaired sperm function. A number of 
assays are available to measure OS including chemilu-
minescence for ROS, total antioxidant capacity for an-
tioxidants, and the malondialdehyde assay for post-hoc 
damage from lipid peroxidation [74-76]. Though useful, 
these tests are difficult to incorporate into routine use 
because they are expensive, complex, and time-sensi-
tive, and may also require complex instrumentation, 
large and neat sample volumes, and extensive techni-
cal training (Table 1) [76]. Additionally, assay results 
do not correlate with one another and provide only a 
single marker of OS-either oxidant levels, antioxidant 
levels, or post-hoc damage [77].
To date, measurement of ROS in semen is not often 
utilized as, depending on the method for ROS assess-
ment, it may be prone to intra- and inter-laboratory 
variability, high turnaround time and high costs 
[58,69,78]. The advent of new technologies that rapidly 
detect seminal OS through the assessment of ORP in 
a reproducible manner using a bench-top analyzer can 
allow for an accurate and cost-effective diagnosis of 
MOSI [76,78,79]. The Male Infertility Oxidative System 
(MiOXSYS) is a recently developed assay for the as-
sessment of ORP [69]. The ORP test is novel in the area 
of infertility and is based on a galvanostatic measure 
of electrons. MiOXSYS has been developed for easy 
and quick measurement of ORP in semen [80]. Several 
studies have validated the reproducibility and reliabil-
ity of the MiOXSYS in measuring ORP levels in semen 
Table 1. Advantages and disadvantages of commonly used techniques to measure seminal oxidative stress
Assay Advantages Disadvantages
ROS by chemiluminescence •  Chemiluminescence is robust
•  High sensitivity and specificity
•  Luminol measures global ROS levels – both  
extracellular and intracellular (superoxide anion, 
hydrogen peroxide, hydroxyl radical)
•  Time-consuming method
•  Requires large and expensive equipment
•  Variables such as semen age, volume, repeated 
centrifugation, temperature control and background 
luminescence may interfere with measurement
TAC •  Rapid colorimetric method
•  Measures total antioxidants in seminal plasma
•  Does not measure enzymatic antioxidants
•  Length of inhibition time is a critical aspect of the test
•  Requires expensive microplate readers
ROS-TAC score •  Better predictor compared with ROS or TAC alone •  Requires statistical modeling
•  Not a direct measure of ROS or TAC, rather a prediction 
of oxidative stress
MDA-TBA adduct detection  
by colorimetry or  
fluoroscopy
•  Measures lipid peroxidation
•  Detects MDA-TBA adduct by colorimetry or  
fluoroscopy
•  Rigorous controls required
•  Non-specific test providing post hoc measure only
ORP •  Provides redox balance in real time
•  Measures all known and unknown oxidants and 
antioxidants
•  Less time-consuming and requires less expertise
•  Can be measured in semen and seminal plasma, 
including frozen specimens
•  Affected by viscosity of the sample
ROS: reactive oxygen species, TAC: total antioxidant capacity, MDA: malondialdehyde, TBA: thiobarbituric acid, ORP: oxidation-reduction poten-
tial. Data from Agarwal et al (Ther Adv Urol 2016;8:302-18) [76].
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samples from patients being evaluated for male infer-
tility [58,69,71,81]. More importantly, ORP levels have 
been shown to be significantly negatively correlated 
with sperm concentration, sperm motility, normal mor-
phology and total motile count [72]. ORP levels are also 
significantly positively correlated with sperm DNA 
fragmentation (SDF) [72,79,81], although normal levels 
of SDF do not exclude the presence of OS. At a cut-
off value of 1.34 (mV/106 sperm/mL), ORP may be used 
to differentiate between normal and abnormal semen 
quality in infertile men with 98.1% sensitivity, 40.6% 
specificity, 94.7% positive predictive value, and 66.6% 
negative predictive value [58,59,69] (Fig. 4). 
Among infertile men, higher ORP levels are observed 
in cases with abnormal semen parameters versus nor-
mal parameters (Fig. 5A, 5B). Analysis of data of 3,966 
patients at Hamad Medical Corporation, Doha, Qatar, 
revealed statistically significant negative correlations 
between ORP and normal sperm morphology (r=-0.529, 
p<0.0001), progressive motility (r=-0.463, p<0.0001), and 
sperm concentration (r=-0.844, p<0.0001). The differ-
ence in ORP between normozoospermic (mean: 1.14±0.97 
mV/106 sperm/mL; median: 0.86 mV/106 sperm/mL) and 
non-normozoospermic (mean: 5.65±11.34 mV/106 sperm/
mL; median: 2.04 mV/106 sperm/mL) patients was also 
significant (p<0.0001) (Fig. 5B). Fig. 5C depicts ORP 
values of asthenozoospermic (mean: 5.63±11.36 mV/106 
sperm/mL; median: 2.03 mV/106 sperm/mL) versus non-
A
S
e
n
s
0 1.0
0
1.0
0.8
0.6
0.4
0.2
0.2 0.4 0.6 0.8
1-Spec
ROC curve
Source of the curve
Static ORP
PR motility
Sperm total
Total motility
Normal morphology
Sperm concentration
Volume
Reference line
Sens: 98.1%
Spec: 40.6%
PPV: 94.7%
NPV: 66.6%
AUC: 0.765
B
O
R
P
(m
V
/1
0
s
p
e
rm
/m
L
)
6
Abnormal
(n=1,893)
9.00
8.00
7.00
6.00
5.00
4.00
3.00
2.00
1.34
1.00
0.00
Normal
(n=199)
Semen analysis group
Fig. 4. (A) A receiver operating characteristic (ROC) curve was used to identify the oxidation-reduction potential (ORP) (mV/106 sperm/mL) cutoff 
that best predicted normal and abnormal semen parameters based on sensitivity (Sens), specificity (Spec), positive predictive value (PPV), nega-
tive predictive value (NPV), and area under the curve (AUC). (B) Distribution of ORP in patients with at least one abnormal semen parameter 
versus patients with normal semen parameters, showing the established cutoff value of 1.34 mV/106 sperm/mL. Data from Agarwal et al (Asian J 
Androl 2019 [in press]) [59].
O
R
P
(m
V
/1
0
s
p
e
rm
/m
L
)
6
0
200
160
120
80
40
Normal semen
parameters
(n=193)
Abnormal semen
parameters
(n=614)
A
O
R
P
(m
V
/1
0
s
p
e
rm
/m
L
)
6
Normozoospermic
(n=357)
Non-no
(n=3,609)
rmozoospermic
B
O
R
P
(m
V
/1
0
s
p
e
rm
/m
L
)
6
Normal sperm
motility
(n=399)
Asthenozoospermic
(n=3,567)
C
0
250
50
40
30
20
150
10
5
0
250
50
40
30
20
150
10
5
Fig. 5. Distribution of oxidation-reduction potential (ORP) values in the infertile men with normal and abnormal semen parameters. (A) Data from 
Cleveland Clinic, Cleveland OH, USA (n=807); (B) Data from Hamad Medical Corporation, Doha, Qatar (n=3,966); (C) Data of asthenozoospermic 
patients from Hamad Medical Corporation, Doha, Qatar (n=3,966).
 Ashok Agarwal, et al: Male Oxidative Stress Infertility
7www.wjmh.org
asthenozoospermic patients (mean: 1.79±3.80 mV/106 
sperm/mL; median: 0.92 mV/106 sperm/mL) [unpub-
lished data].
MANAGEMENT AND TREATMENT 
OF MALE OXIDATIVE STRESS 
INFERTILITY (MOSI)
Despite significant advances in the diagnosis and 
management of male infertility, there are no evidence-
based treatment guidelines available for idiopathic 
male infertility. Understandably, it is difficult to de-
velop an evidence-based approach for a condition with 
an unclear etiology. A survey among members of the 
American Urological Association (AUA) indicated that 
two-thirds of clinicians use empirical medical therapy 
(EMT) such as selective estrogen receptor modula-
tors, aromatase inhibitors, and gonadotropins to treat 
idiopathic male factor infertility [82]. While the role 
of hormonal therapy in men with an identified ab-
normality such as hypogonadotropic hypogonadism is 
well-defined [83], endocrine imbalance is responsible for 
approximately 10% of all known causes of infertility 
[21]. The literature remains inconclusive and controver-
sial regarding off-label EMTs for men with idiopathic 
infertility [20,82,84-87], especially in light of their cost 
Table 2. Empiric medical treatment for idiopathic male infertility (ICD10 Code: Z31.41)
Medication Administration
Common  
dosages
Adverse effects
Estimated cost  
per 3 months
Selective estrogen receptor modulators
    Clomiphene citratea Oral 50 mg daily Hot flashes, weight gain, gynecomastia, hair 
loss, dizziness, gastrointestinal distress
$185.40c 
    Tamoxifen citratea Oral 20 mg daily See above $99.60c
Aromatase inhibitors
    Anastrozolea Oral 1 mg, 3 times/wk Decreased libido, headache, elevated liver 
function tests 
$35.40c
    Human chorionic-
gonadotropinb
Subcutaneous 1,500–3,000 IU,  
3 times/wk
Injection site pain, headache, depression, 
gynecomastia, hyperglycemia
$337.50–$675.00d
   Recombinant follicle-
stimulating hormoneb
Subcutaneous 75 IU, 3 times/wk Injection site pain $2,160.00d
aOff label use; bFood and Drug Administration approved for treatment of infertility secondary to gonadotropin deficiency; cAverage cost at 
Walmart, CVS and Walgreens; dCompound pharmacy cost.
Table 3. Antioxidant classification in relation to its action on sperm characteristics 
Type Function References
Enzymatic:
   Superoxide dismutase First line defense antioxidants  [94,95]
   Catalase First line defense antioxidants  [54,96]
   Glutathione peroxidase Scavenges lipid peroxides and hydrogen peroxide  [97,98]
   Glutathione reductase Scavenges lipid peroxides and hydrogen peroxide  [99]
Non enzymatic:
   Vitamin C Neutralizes free radicals  [100,101]
   Vitamin E Neutralizes free radicals  [102,103]
   Ferritin and carnitines Neutralizes free radicals and acts as an energy source  [126]
   Coenzyme Q10 In its reduced form, scavenges free radicals intermediate in mitochondrial electron transport system  [104]
   Transferrin Sperm vitality, DNA integrity and OS homeostasis  [105]
   Zinc Formation of free oxygen radicals and sperm chromatin stability  [106]
   Selenium Sperm motility and OS homeostasis  [107]
   N-acetyl L-cysteine Free radical scavenging activity  [108,109]
   L-arginine Formation of free oxygen radicals  [110]
   Folic acid Sperm DNA integrity  [111]
OS: oxidative stress.
https://doi.org/10.5534/wjmh.190055
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and side effects (Table 2). Although there are several 
small studies that provide support for pharmacological 
EMT to treat idiopathic male infertility, there is a lack 
of robust placebo-controlled trials demonstrating im-
proved live birth outcomes [87-90]. 
For the vast majority of infertile men with no un-
derlying endocrine, bacterial, genetic or anatomical 
causes of infertility, an alternative approach may be to 
shift from administering EMTs to identifying potential 
sources of MOSI and mitigating the sequela. The hu-
man body produces endogenous antioxidants in an ef-
fort to prevent the damage caused by ROS [91,92], but 
this response is not always adequate, resulting in OS. 
Several studies have shown that exogenous antioxi-
dants have the capacity to counteract oxidative dam-
age or OS, improving both sperm motility and DNA 
integrity for infertile men with OS (Table 3) [87-91,93-
111]. Indeed, many oral formulations of antioxidants 
are readily available in the market and are commonly 
used to treat men with infertility. However, there is 
growing awareness that the indiscriminate use of an-
tioxidants may paradoxically exacerbate sperm cell 
damage in men without elevated MOSI by inducing 
a state of reductive stress [52,112]. In order to prevent 
the inappropriate use of antioxidants, clinical guide-
lines outlining the effective diagnosis and treatment of 
MOSI are critical. Several clinical trials and systemic 
reviews involving the use of various combinations of 
Table 4. Effect of antioxidants on male infertility: Double blind placebo controlled studiesa
Study reference Infertility type Cases Antioxidants Duration Outcome
Micic et al  
(2019) [119]
Idiopathic oligo-
asthenozoo-
spermia
Placebo group (n=50)
Treatment group 
(n=125)
Proxeed plus=2 times/d
•  LC=1,000 g, LAC=0.5 g,  
fumarate=0.725 g, fructose=1 g, 
citric acid=50 mg, zinc=10 mg, 
coenzyme Q10=20 mg,  
selenium=50 µg, Vit C=90 mg, 
folic acid=200 µg, Vit B12=1.5 µg
3 months Increase in semen 
volume, progressive 
motility and vitality
Decrease in sperm 
DNA fragmentation 
index
Busetto et al  
(2018) [113]
Idiopathic OAT, 
with and with-
out varicocele
Varicocele (n=45)
Without varicocele 
(n=49)
LC=1,000 mg, LAC=500 mg,  
fumarate=725 mg, fructose= 
1,000 mg, Coenzyme Q10=20 
mg, Vit C=90 mg, Zinc=10 mg,  
folic acid=200 μg, Vit B12=1.5 μg
6 months Increase in sperm 
concentration, total 
sperm count, motil-
ity, and progressive 
motility
Safarinejad et al 
(2012) [116]
Idiopathic  
infertility
Placebo group (n=114)
Treatment group 
(n=114)
Coenzyme Q10=200 mg/d 26 weeks Increase in sperm 
concentration, 
motility and normal 
sperm morphology
Safarinejad  
(2009) [114]
Idiopathic OAT Placebo group (n=106)
Treatment group 
(n=106)
Coenzyme Q10=300 mg/d 26 weeks Increase in sperm 
concentration and 
motility
Balercia et al  
(2009) [120]
Idiopathic  
asthenozoo-
spermia
Placebo group (n=30)
Treatment group (n=30)
Coenzyme Q10=200 mg/d 3 months Increase in sperm 
concentration and 
motility
Tremellen et al 
(2008) [28]
Male factor  
infertility
Placebo group (n=20)
Infertile men (n=40)
Menevit=1 capsule/d
•  Lycopene=6 mg, Vit E=400 IU,  
Vit C=100 mg, Zinc=25 mg, 
selenium=26 μg, folate=0.5 
mg, garlic-1,000 mg, palm oil 
(vehicle)
3 months Improved pregnancy 
rates in couples 
undergoing IVF-ICSI 
treatment for severe 
male factor infertility
Balercia et al  
(2005) [115]
Idiopathic 
asthenozoo-
spermia
Placebo group (n=15)
Treatment group 
(n=45): 
LC group: n=15;  
LAC group: n=15; 
LC+LAC group: n=15
LC=3 g/d
LAC=3 g/d
LC+LAC=2 g+1 g/d
6 months Increase in sperm 
motility and normal 
sperm morphology
OAT: oligoasthenoteratozoospermia, LC: L-carnitine, LAC: L-acetylcarnitine, Vit: vitamin, IVF-ICSI: in vitro fertilization/intracytoplasmic sperm in-
jection. aOnly double blind placebo control studies on idiopathic male infertility patients were included. Except for three studies (94, 96, and 142), 
others used a combination of antioxidant supplements for a period of 3 to 6 months.
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antioxidants (L-carnitine, selenium, N-acetyl-cysteine, 
Coenzyme Q10, ubiquinol, vitamin E, vitamin C, and 
lycopene) in infertile men have reported beneficial ef-
fects of antioxidants on sperm concentration, motility, 
and DNA integrity (Table 4) [113-120]. Preliminary re-
sults from a 2018 clinical trial involving 148 idiopathic 
infertile men indicated that intake of oral antioxidants 
for a period of three months significantly increased 
sperm concentration (36%, p<0.0001), progressive motil-
ity (100%, p<0.0001), and motility (12%, p=0.0033). More-
over, a significant decrease in ORP (39%, p<0.0001) 
and SDF (20%, p=0.0002) was observed post-treatment 
[unpublished data]. These beneficial changes in semen 
quality have been reported to improve the chance of 
natural conception in several but not all studies [53,121]. 
This benefit could be augmented, and harm prevented, 
by directing therapy through measuring and monitor-
ing seminal ORP [113-116,122,123].
Identifying and treating MOSI in cases where the 
use of assisted reproductive technology (ART) is in-
dicated is especially important, as many of the sperm 
preparation and handling methods used during ART 
may induce OS, further aggravating the negative im-
pact of MOSI [124,125]. In couples undergoing ART, 
diagnosis of MOSI and subsequent antioxidant therapy 
may improve ART success [122,126,127]. Additionally, 
there is emerging evidence that antioxidant therapy 
may improve pregnancy outcomes in couples with re-
current pregnancy loss [128]. Evidence-based guidelines 
should provide recommendations on ways to best man-
age other causes of OS, including lifestyle modifications 
(improved diet, smoking cessation, exercise, and weight 
loss), treatment of clinically relevant varicoceles, and 
treatment of male accessory gland infection (MAGI) 
as well as other inflammatory pathologies linked with 
MOSI (Fig. 3). The treatment of MAGI with antibiot-
ics, and the decrease in the numbers of ROS-producing 
seminal leukocytes using anti-inflammatories are like-
ly to add benefit in combination with neutralization 
of ROS by antioxidant therapy [129-132]. Treatment 
success and adherence for the above conditions can be 
monitored by measuring seminal ORP, as well.
The diagnosis and management of idiopathic male 
infertility is an integral component of comprehensive 
sexual and reproductive health services. Idiopathic 
male infertility can be an emotional burden and fi-
nancial strain for couples. Current treatment proto-
cols for male infertility are not evidence-based and 
have the potential risk of complications and increased 
healthcare-related expenditures [20,84]. MOSI provides 
clinicians and patients with a diagnostic classification 
to guide future research and treatment, while simul-
taneously reducing apprehension and uncertainty for 
many couples. A recent consensus guideline by the Eu-
ropean Society for Human Reproduction & Embryology 
(ESHRE) concluded that there is currently insufficient 
evidence to support the use of antioxidants for male 
infertility due to lack of a standardized measure of OS 
C
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Clinic
2019
Testing
Basic
semen
analysis
OS evaluation
by
ORP (MiOXSYS)
OS
ORP>
1.34 mV/10 sperm/mL
6
Treatment
Inflammation/
leukocytospermia
(prostatitis, MAGI)
Antioxidant+antibiotics
anti-inflammatory
Retest for MOSI
Counsel on
appropriate changes
Antioxidant
supplementation
Retest for MOSI
with ORP
Lifestyle
(smoking, obesity, etc.)
MOSI
Varicocelectomy
Varicocele
Retest for MOSI Retest for MOSI
Fig. 6. Treatment options for male oxi da-
tive stress infertility. OS: oxidative stress, 
ORP: oxidation-reduction potential, MiOX-
SYS: Male Infertility Oxidative Sys tem, 
MAGI: male accessory gland infection, 
MOSI: Male Oxidative Stress Infertility.
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and inconsistent selection of eligible patients across 
studies [133]. MOSI diagnosis combined with ORP mon-
itoring may provide a more targeted, reliable approach 
for using antioxidant therapy in both research and 
practice.
Compared with hormonal EMT and ART, antioxi-
dants are relatively safe, inexpensive and widely avail-
able, with a growing body of data supporting their 
effectiveness at improving semen parameters and live 
birth rates [53]. Further clinical studies are indicated 
to directly compare live birth rates among men with 
MOSI assigned to receive antioxidants versus EMT and 
ART. Treatment guidelines providing individualized 
antioxidant therapy protocols based on ORP status for 
men with MOSI could provide a significant advance-
ment in the management of male factor infertility and 
facilitate future investigations (Fig. 6) [134]. Guidelines 
are also necessary to avoid possible overuse of anti-
oxidants leading to reductive stress, which can be as 
detrimental to sperm health as OS [52,135-137] and has 
been associated with defects in embryogenesis [138]. 
Supra-physiologic levels of antioxidants may also scav-
enge the ROS necessary to induce sperm capacitation 
[32,38], leading to infertility. Because antioxidants are 
readily available online or over-the-counter, they may 
appear to be a benign first-line treatment. Without 
clear guidelines for appropriate use, however, there is a 
risk of overuse in men without evidence of MOSI who 
may then experience delay accessing more effective 
therapies (e.g., ART or varicocele repair). Therefore, the 
oxidative status of male infertility patients should be 
evaluated before antioxidants are recommended and 
used only in those cases where MOSI is present.
RECOMMENDATIONS AND FUTURE 
DIRECTIONS
Therefore, the authors recommend that men with 
idiopathic infertility should be screened for MOSI us-
ing an efficient, inexpensive, high sensitivity/specific-
ity test for ORP such as MiOXSYS, which has practi-
cal advantages over alternative techniques (Table 1). 
Those men screening positive for MOSI should then 
undergo more extensive examination to identify treat-
able triggers and be counseled on appropriate steps 
to mitigate known causes of OS (e.g., smoking, alcohol 
consumption, lifestyle risk factors, radiation, toxins, 
etc.) [139,140]. ORP testing should be repeated no less 
than 3 months following the appropriate management 
plan in infertile men with no explanation for MOSI. 
Ultimately, infertile men with MOSI should be advised 
to take antioxidants for a minimum of three months 
after other known causes of OS have been eliminated. 
Infertile men without MOSI should be advised against 
antioxidant therapy. Follow-up testing of ORP levels is 
recommended to confirm compliance and monitor the 
efficacy of antioxidant supplementation and contin-
ued lifestyle changes 6 to 8 weeks post treatment. We 
recommend that these approaches be tested in double 
blind randomized controlled trials to establish whether 
time to pregnancy and live birth rate is improved 
in couples where the man is undergoing antioxidant 
treatment.
With the increasing awareness and understanding 
of MOSI as a distinct male infertility diagnosis, the 
development of evidence-based guidelines that target 
the underlying causes, while balancing the risks and 
benefits of individual therapies, is imperative. The au-
thors feel that measurement of ORP and stratification 
of male fertility/infertility on the basis of ORP will 
be an important tool in the management of infertile 
couples. The exact role will be defined in future trials 
and could validate a reclassification of male infertility 
that incorporates MOSI as a diagnostic category. A bet-
ter understanding of the etiology of this diagnosis will 
help identify those men likely to benefit from antioxi-
dant therapy while minimizing the harmful effects of 
antioxidant overdosing. 
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Appendix. Key terminologies
MOSI Infertile men with abnormal semen characteristics and oxidative stress, which includes many patients who were previously 
classified as having idiopathic male infertility.
ROS Reactive oxygen species (ROS) are compounds of oxygen radicals such as superoxide anion (O2
–), hydrogen peroxide (H2O2), 
hypochlorite (OHCl), and hydroxyl radical (OH) containing free, unpaired electrons in their outer orbit, which makes them 
highly unstable and reactive [57]. 
MiOXSYS MiOXSYS is a novel technology used to measure oxidation-reduction potential (ORP) in semen based on a galvanostatic 
measure of electrons [58].
ORP ORP is a measure of the relationship between oxidants and antioxidants that provides a comprehensive measure of the 
redox system. ORP cut-off value 1.34 mV/106 sperm/mLv identified normal semen and abnormal semen quality with a 
sensitivity 98.1%, specificity 40.6%, positive predictive value 94.7% and negative predictive value 66.6% [59]. 
Indication of seminal ORP includes men with abnormal semen analysis and male infertility.
Oxidative stress Oxidative stress occurs (OS) when there is an imbalance between ROS and the antioxidants that scavenge surplus free 
radicals [24].
Reductive stress A shift of the bodily redox levels into a more reduced state is called reductive stress. Overdosing on antioxidants causes 
reductive stress [52].
